Ozempic Mention in Filing

can you get me mentions of Ozempic in company filings in 2023?

Here are the mentions of Ozempic in company filings in 2023:

1. NOVO NORDISK A/S - Filing Date: April 13, 2023:

   • The company reported a sales growth of 25% and operating profit growth of 28% for the first three months of 2023.
   • The sales outlook for 2023 was raised, primarily due to prescription trends of Wegovy® in the first quarter and higher full-year expectations for Wegovy® sales in the US.
   • Additionally, the updated sales outlook reflects higher full-year expectations for Ozempic® sales, mainly in the US, following accelerated volume growth of the GLP-1 class【0†source】.

2. Viatris Inc - Filing Date: February 27, 2023:

   • Viatris Inc mentioned working on various development programs, including the potential to be first to market for generics of several drugs, including Ozempic®.
   • They are also working with partners on novel and complex products, like biosimilars and long-acting injection versions of approved drugs.
   • Their R&D organization focuses on delivering new product opportunities across all categories and markets, with an emphasis on development activities in areas like biosimilars and modified release injectables【1†source】.

These snippets provide insights into the companies' strategic directions and expectations regarding Ozempic and related products in their portfolios.

Go all the way to Nov 2023

As of November 2023, there is a notable mention of Ozempic in the filings of DaVita Inc., dated November 7, 2023:

• DaVita Inc. highlighted developments in the healthcare marketplace related to new or innovative technologies, drugs, and treatments that could impact the growth rate of the End-Stage Kidney Disease (ESKD) patient population or reduce the demand for dialysis treatments.
• Specifically, they mentioned a clinical study for Novo Nordisk's Ozempic®, a glucagon-like peptide 1 (GLP-1) receptor agonist, which was stopped early for efficacy in October 2023.
• This development created uncertainty in the marketplace regarding the potential impact of Ozempic® and similar classes of drugs on the growth rate of the ESKD patient population.
• DaVita Inc. expects that further information on GLP-1s and their potential application to kidney care will be released by third parties later in 2023 and the first half of 2024.
• The release of such information, or any other information regarding current or future new or innovative technologies, drugs, and treatments, may drive volatility in DaVita Inc.'s stock price.
• They also noted that any sustained or significant decline in the growth rate of the ESKD patient population or demand for their services, whether due to new technologies, drugs, treatments, or otherwise, could materially impact their business, operations, financial condition, cash flows, and stock price【0†source】.

This snippet indicates the potential impact of Ozempic® on the healthcare market, specifically in relation to kidney care and the ESKD patient population.